MedGenome

Cloning of genes into various plasmids and retroviral constructs

Transfection of your insert-containing plasmid into your cell line of choice
We offer plasmid and retroviral based gene delivery
Single foci selection and enrichment of clones using antibiotic selection or flow-sorting
Stable cell line expansion
Validation of stable cell lines with western blot (with positive & negative controls) and/ or flow-cytometry, cell-based assays
CRISPR/CAS9 based gene alterations

Our scientists will work closely with your R&D team to help optimize all parameters specific to your cell line(s) of interest

T cells are the core components of our adaptive immune system. Once activated, they can directly kill cells that are foreign (cytolytic T-cells) or perform helper function (helper T-cells) to activate B-cells to make antibodies against foreign antigen. The activation of T-cells involve recognition of MHC-peptide complex by the T-cell receptors (TCR). We carry >109 T-cells, each expressing a unique TCR. This highly diverse repertoire of T-cells has the ability to recognize peptides originating from foreign elements such as invading pathogens and cancer cells. Each TCR recognize peptides in complex with MHC proteins presented on the surface of antigen presenting cells. Productive T-cell activation results in the clonal expansion of a specific T-cell and this expansion can be accurately determined by TCR sequencing. In cancer, TCR sequencing has predictive and prognostic value and can lead to the development of novel therapeutics such as engineered T-cells.

ChIP-seq is a powerful method to map transcription factor binding sites and histone modification status on a genome-wide scale. This technique is a combination of chromatin immunoprecipitation assays with sequencing. Main steps in the ChIP-seq include cross-linking a protein to chromatin, shearing the chromatin, using a specific antibody to precipitate the protein of interest with its associated DNA, reverse cross linking and finally purifying the associated DNA fragments.

MedGenome has state-of-the-art Next Generation Sequencing Illumina platforms Miseq, Hiseq 4000 / 2500 and X10 at its facilities in Foster City, California and Bangalore, India.

miRNA Sequencing is also a type of RNA-Seq with the only difference being that the input is enriched for small RNAs. miRNA enables researchers to study tissue-specific expression patterns, isoforms of miRNAs, disease relationships and to find out novel uncharacterized miRNAs.

With unprecedented sensitivity and dynamic range, small RNA sequencing methods allow for the most accurate detection and quantification of rare small RNA sequences.

MedGenome has state-of-the-art Next Generation sequencing Illumina platforms Miseq, Hiseq 4000 / 2500 and X10 at its facilities in Foster City, California and Bangalore, India.

Proprietary immuno-oncology solutions for tumor microenvironment analysis and neo-epitope

RNA Sequencing is a powerful technique that allows researchers to study the complete transcriptome profiling. A transcriptome is a complete set of transcripts, which includes their quantities as available in the cell, for specific physiological conditions. A complete understanding of the transcriptome gives enormous information on the functional components of the genome, molecular components of cell, tissues and knowledge on disease development.

Different technologies such as Hybridization-based, and sequence-based approaches, and specialised microarrays have also been used earlier to study the transcriptome, but they were found to not be very effective for large volumes of data. Development of RNA-Seq based on the high-throughput DNA sequencing method has solved that problem to a great extent.

MedGenome has state-of-the-art Next Generation Sequencing Illumina platforms Miseq, Hiseq 4000 / 2500 and X10 at its facilities in Foster City, California and Bangalore, India.

Whole Exome Sequencing (WES), also known as Targeted exome capture is sequencing the protein coding sequences of genome (exomes) rather than the complete genome. It is estimated that the protein coding regions of the human genome constitute about 85% of the disease-causing mutations.

Exome sequencing is done to identify the functional variation that is responsible for both Mendelian and common diseases. Most of the diseases or phenotypes are caused by variations in coding regions, and so it is an alternative for Whole Genome Sequencing based on a research question.

MedGenome has state-of-the-art Next Generation sequencing Illumina platforms Miseq, Hiseq 4000 / 2500 and X10 at its facilities in Foster City, California and Bangalore, India.

Whole Genome Sequencing (WGS) provides complete information on genetic makeup of organisms, enabling researchers to study variations within the species and compare them with others which can help in solving unanswered puzzles in the Genomics and providing fuel for research for biomarker discovery and personalized medicine.

MedGenome has state-of-the-art Next Generation Sequencing Illumina platforms Miseq, Hiseq 4000 / 2500 and X10 at its facilities in Foster City, California and Bangalore, India.

WGS can reveal germline variation, Somatic Variation, Copy number variation, changes in Transposable Elements, and Structural variants.

Comprehensive bioinformatics capabilities to support advanced and custom analysis on genomics data.

Data analysis

• Variant calling
  
• Gene expression
  
• T-cell neo-epitope identification
  
• Tumor microenvironment analysis
  
• Epigenetic regulation
  
• Genotype – phenotype correlation
  
• Gene signature analysis
  

Data sources

• Mouse studies
  
• Primates
  
• Microbiome
  
• Human preclinical and clinical trials
  

Data type

• Whole Genome analysis
  
• Exome
  
• RNAseq
  
• Chipseq
  
• Methylseq
  
• miRNA
  
• Small RNA analysis
  
• Microarray
  
• Clinical
  

Disease areas

• Oncology
  
• Neurology
  
• Cardiovascular
  
• Diabetes
  
• Ophthalmology
  
• ENT
  
• Autoimmune
  
• Pre-natal
  
• Rare diseases
  
• Population Genomics/Longevity